Welcome to our dedicated page for Insight Molecular Diagnostics SEC filings (Ticker: IMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insight Molecular Diagnostics Inc.'s SEC filings document a molecular diagnostics issuer developing donor-derived cell-free DNA assays for transplant monitoring. Current reports and proxy materials cover operating results, GraftAssure product disclosures, regulatory and clinical-development updates, investor-presentation materials, and capital-structure matters tied to financing and equity compensation.
Its filings also describe governance subjects including shareholder voting provisions, bylaws, board and executive compensation matters, equity incentive plan awards, and material agreements for specimen collection services related to GraftAssureCore testing.
Insight Molecular Diagnostics reported a sharply smaller business in early 2026 but an improved bottom line driven by non-cash items and new equity capital. For the quarter ended March 31, 2026, net revenue was just $32 thousand versus $2.1 million a year earlier, as all revenue came from laboratory services in the United States. Despite this, net loss narrowed to $4.3 million from $6.7 million, helped by a $5.9 million decrease in the fair value of Chronix-related contingent consideration.
Operating expenses fell to $4.4 million from $8.1 million, while net cash used in operating activities increased to $7.6 million. The company strengthened liquidity through a February 2026 registered direct offering that generated $26.0 million in gross proceeds and about $24.6 million in net proceeds, contributing to $28.2 million in cash and cash equivalents at quarter-end. Total assets were $40.4 million, with $51.1 million in liabilities and a shareholders’ deficit of $10.7 million. Management concluded that, despite ongoing expected losses and negative operating cash flows, existing resources are sufficient to meet projected needs for at least 12 months, so substantial doubt about continuing as a going concern has been alleviated for this period.
Insight Molecular Diagnostics reported Q1 2026 results and highlighted progress toward commercializing its GraftAssure kidney transplant rejection tests. Net revenue was just $32,000, down sharply from $2.1 million a year earlier, as the lab focused on research supporting its FDA submission instead of revenue-producing work.
The company generated gross profit of $15,000 and recorded a GAAP net loss of $4.3 million, or $0.12 per share. On a non-GAAP basis, adjusted net loss was $9.6 million and adjusted EBITDA loss was $9.1 million, reflecting higher investment in R&D, sales and marketing ahead of launch.
Cash, cash equivalents and restricted cash totaled $29.4 million at quarter-end, strengthened by a $26.0 million registered direct offering that delivered about $24.6 million in net proceeds. Management described encouraging FDA dialogue on GraftAssureDx, early research-use kit orders in Europe and Asia, and growing engagement in the GALACTIC registry study as it targets a large transplant monitoring market.
Insight Molecular Diagnostics Inc. (iMDx) is asking shareholders to approve four items at its 2026 virtual annual meeting, including re-electing four directors, ratifying CBIZ CPAs as auditor, a non-binding say-on-pay vote, and a 1,750,000-share increase to its 2018 Equity Incentive Plan for a new total of 5,550,000 shares.
The proxy highlights iMDx’s strategy to decentralize transplant organ health monitoring through its dd-cfDNA assay platform. The company has submitted its GraftAssureDx test kit to the FDA for in vitro diagnostic marketing authorization and is running a 5,000-patient registry across 50 hospitals, supported by a partnership with Bio-Rad Laboratories, which owns just under 10% of iMDx.
As of the April 27, 2026 record date, iMDx had 32,288,039 common shares outstanding. The filing also details board independence, committee structures, a clawback policy, an insider trading policy that prohibits hedging, and 2024–2025 compensation and equity awards for directors and named executive officers.
Insight Molecular Diagnostics Inc. filed a current report to correct an exhibit previously attached to its Annual Report on Form 10-K for the year ended December 31, 2025. The earlier filing inadvertently included shareholder voting provisions that are not part of the Company’s Third Amended and Restated Bylaws.
The Company is now providing the correct copy of its Third Amended and Restated Bylaws as Exhibit 3.1 to this report. The correction is described as a clerical error and does not change any other disclosures contained in the Form 10-K.
Broadwood Partners, Broadwood Capital and Neal C. Bradsher report beneficial ownership of 12,835,134 Insight Molecular Diagnostics shares, representing 39.7% of the common stock. The amendment reflects an updated ownership percentage based on 32,318,071 shares outstanding, adjusted to include warrants they beneficially own.
Broadwood Partners and Broadwood Capital each report shared voting and dispositive power over 12,834,977 shares, while Mr. Bradsher also holds 157 shares with sole voting and dispositive power. The group funded its investment from working capital and personal funds, without dedicated borrowing beyond ordinary-course working capital.
The reporting persons state they will continue to review their investment and may discuss strategic alternatives with management, the board and other shareholders, and reserve the right to pursue various transactions or actions in compliance with securities laws.
Insight Molecular Diagnostics Inc. insider Broadwood Partners, L.P., together with related entities, reported net open-market purchases of 570,184 shares of IMDX common stock. The buys occurred between April 23 and April 27 in multiple tranches at weighted average prices around $3.50–$3.64 per share.
After these transactions, entities associated with Neal C. Bradsher report holding 12,684,884 shares of common stock, plus warrants currently exercisable for a total of 300,186 additional shares at an exercise price of $30.60 per share that expire on April 19, 2027.
Insight Molecular Diagnostics Inc. shareholder entities associated with Broadwood Partners, L.P. and Neal C. Bradsher reported open-market purchases of 182,861 shares of common stock. The shares were bought between April 16 and April 20 at weighted average prices of $3.4457, $3.5711, and $3.8822 per share, across specified price ranges disclosed in the footnotes.
Following these transactions, Broadwood Partners is shown with 12,114,700 indirectly owned Insight Molecular common shares, while Neal C. Bradsher directly owns a small additional common stock position. The filing also lists currently exercisable warrants, held both directly and indirectly, each for 150,093 underlying shares at an exercise price of $30.60 per share expiring on April 19, 2027.
Insight Molecular Diagnostics Inc. Chief Financial Officer James Andrea reported routine equity compensation activity. On March 26, 2026, 28,302 Restricted Stock Units (RSUs) vested into an equal number of common shares under the company’s 2018 Equity Incentive Plan.
The company withheld 11,298 common shares at $4.11 per share to cover required tax obligations, and the filing states that the reporting person did not sell any shares. After these transactions, he directly holds 206,060 common shares and 84,905 RSUs. The RSU award vests over four years, with 25% vesting on March 26, 2026 and the remaining 75% vesting in equal annual installments, subject to continued service.